Results 221 to 230 of about 127,902 (310)

Association of Neurodevelopmental Disorders and Congenital Anomalies With Prenatal Multiple Sclerosis Treatment—Real‐World Historical Cohort Study

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1565-1573, June 2026.
There is a paucity of data regarding the effects of prenatal disease‐modifying therapies (DMTs) for multiple sclerosis (MS), on congenital anomalies in the offspring. Moreover, data on the association with neurodevelopmental disorders are lacking. This is an historical cohort study, within the Israeli Clalit Health Services database (2005–2024) that ...
Bar Rosh, Ofek Levi, Nili Stein, Amir Yahav, Naomi Gronich   +4 more
wiley   +1 more source

RXR Gamma Enables Oligodendrocyte Differentiation by Suppressing Sonic Hedgehog Signaling

Glia, Volume 74, Issue 6, June 2026.
Using pharmacogenetic approaches, Baldassarro et al. demonstrate that RXRγ suppresses the SHH signaling pathway in OPCs to ensure their efficient differentiation following T3 stimulation. Accordingly, Rxrg−/− OPCs displayed compromised differentiation which was normalized by the pharmacological inhibition of the hyperactive SHH pathway.
Vito Antonio Baldassarro, Quentin Brassart, Valérie Fraulob, Laura Calzà, Wojciech Krezel   +4 more
wiley   +1 more source

The clinical diversity of primary hypothyroidism presenting as a spontaneous ovarian hyperstimulation syndrome. [PDF]

Endocrinol Diabetes Metab Case Rep
Prabha K, Jebasingh KF, Londhe V, Thomas N.   +3 more
europepmc   +1 more source

Childhood cancer: late effects of cancer treatment [PDF]

, 2007
Vandecruys, Els
core   +1 more source

Impact of Frequent Immune‐Mediated Adverse Events on Treatment Continuity and Outcomes During Durvalumab Plus Tremelimumab Therapy for Unresectable Hepatocellular Carcinoma

Liver International Communications, Volume 7, Issue 2, June 2026.
ABSTRACT Durvalumab plus tremelimumab (Dur/Tre) is the first‐line treatment for unresectable hepatocellular carcinoma (uHCC). Immune‐mediated adverse events (imAEs) are common; however, the impact of specific imAE types on treatment persistence and outcomes remains unclear.
Tomomitsu Matono, Toshifumi Tada, Atsushi Hiraoka, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Tanaka, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Atsushi Naganuma, Hisashi Kosaka, Hidekatsu Kuroda, Yutaka Yata, Hiroki Nishikawa, Michitaka Imai, Tomoko Aoki, Hironori Ochi, Hideyuki Tamai, Shohei Komatsu, Hideko Ohama, Fujimasa Tada, Shinichiro Nakamura, Kazuhiro Nouso, Asahiro Morishita, Norio Itokawa, Tomomi Okubo, Taeang Arai, Akemi Tsutsui, Takuya Nagano, Kazunari Tanaka, Takanori Matsuura, Yoshihide Ueda, Yuichi Koshiyama, Yuki Kanayama, Hidenao Noritake, Hirayuki Enomoto, Kosuke Matsui, Masaki Kaibori, Takumi Fukumoto, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada, on behalf of the RELPEC Group and HCC 48 Group   +53 more
wiley   +1 more source

Neonatal Surveillance Gaps in Maternal Graves' Disease: Findings From a Queensland Maternity Hospital

Australian and New Zealand Journal of Obstetrics and Gynaecology, Volume 66, Issue 3, June 2026.
ABSTRACT Background Graves' disease presents unique challenges in pregnancy due to the risk of neonatal morbidity and mortality from maternal TSH Receptor antibodies (TRAb). A maternity hospital in Queensland has implemented a policy to identify at‐risk neonates and facilitate follow‐up, including cord blood TRAb, thyroid function tests (TFTs), and ...
Umesha Pathmanathan, Annabel Wingate, Stephanie Teasdale   +2 more
wiley   +1 more source

Frequent Seronegative Primary Hypothyroidism in Myxedema Coma in Japan: Three Case Reports With a Systematic Review. [PDF]

Case Rep Endocrinol
Okuno Y, Mukai K, Tamura Y, Hayakawa T, Fukuhara A, Shimomura I.   +5 more
europepmc   +1 more source

Pre‐RAI Monocyte‐to‐Lymphocyte Ratio Predicts Early and Higher Recurrence Risk in Intermediate‐Risk DTC, While PNI and NRI Show No Prognostic Value

Clinical Endocrinology, Volume 104, Issue 6, Page 670-681, June 2026.
ABSTRACT Objective Differentiated thyroid carcinoma (DTC) has an excellent prognosis, but recurrence remains a clinical concern, especially in intermediate‐risk patients. Current stratification systems focus primarily on tumor characteristics, overlooking the host's biological capacity to counteract tumor progression.
Tommaso Piticchio, Francesco Galeano, Salvatore Volpe, Antonio Prinzi, Ignazio Barca, Andrea Scuto, Rosario Le Moli, Giulio Geraci, Andrea Tumminia, Sium Wolde Sellasie, Francesco Pallotti, Francesco Frasca   +11 more
wiley   +1 more source